Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Adaptive Biotechnologies Corporation (ADPT) is a Biotechnology company based in US with a market capitalization of $2.5B. Revenue grew 54.8% year-over-year and free cash flow was negative at -$48.9M. This page tracks ADPT's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 619 employees · IPO Jun 27, 2019

Valuation

Valuation & price

$13.18as of May 15, 2026· -41.1% vs 52w high

P/E ratio

Latest-FY diluted EPS

11.26

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$21.19$15.71$10.24Jul 25Dec 25Jul 26
$10.2452-week range$22.37
Loading valuation history…

Fundamentals

Key fundamentals

$2.5B

Market cap

54.8%

Revenue growth (YoY)

74.2%

Gross margin

-$48.9M

Free cash flow (USD)

$53.6M

Net debt

3.1%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20172025

$38.4M$277M

Free cash flow by year

20172025

-$37.4M-$48.9M

Gross margin by year

20212025

68.1%74.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

17

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 5, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellJun 30, 2026Filing

    Insider Sell $3.5M · 10b5-1 PlanBENZENO SHARON · Chief Commercial Ofc Imm Med · $3.5M

  • Insider sellJun 29, 2026Filing

    Insider Sell $102K · 10b5-1 PlanBOBULSKY SUSAN · Chief Commercial Officer, MRD · $102.5K

  • Insider sellJun 29, 2026Filing

    Insider Sell $1.1M · 10b5-1 PlanGRIFFIN MICHELLE RENEE · Director · $1.1M

  • 8-K eventJun 22, 2026Filing

    Convertible Notes Indenture

  • Insider sellJun 17, 2026Filing

    Insider Sell $1.8M · 10b5-1 PlanROBINS HARLAN S · Chief Scientific Officer · $1.8M

  • Insider sellJun 15, 2026Filing

    Insider Sell $95K · 10b5-1 PlanBOBULSKY SUSAN · Chief Commercial Officer, MRD · $95K

  • 8-K eventJun 15, 2026Filing

    Convertible Notes Offering

  • 8-K eventJun 9, 2026Filing

    Annual Meeting Results

  • Insider sellJun 8, 2026Filing

    Insider Sell $198K · 10b5-1 PlanBOBULSKY SUSAN · Chief Commercial Officer, MRD · $198K

  • Insider sellJun 8, 2026Filing

    Insider Sell $695K · 10b5-1 PlanLO FRANCIS · Chief People Officer · $695.1K

Questions

Frequently asked questions

What is Adaptive Biotechnologies Corporation's market cap?

Adaptive Biotechnologies Corporation (ADPT) has a market capitalization of $2.5B.

What is ADPT's P/E ratio?

A meaningful P/E ratio is not available for ADPT — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ADPT's price-to-book (P/B) ratio?

ADPT trades at 11.26 times book value per share.

Are insiders buying ADPT stock?

SEC Form 4 filings show no open-market insider buys at Adaptive Biotechnologies Corporation in the last 90 days (17 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.